Elörehaladott stádiumú Hodgkin-kóros betegek kezelése CCNU, etoposide és prednimustine (CEP) terápiával.

Translated title of the contribution: Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)

A. Illés, A. Bányai, G. Szegedi

Research output: Contribution to journalReview article


The authors treated 21 advanced, pretreated Hodgkin's disease patients with CEP (CCNU, etoposide, prednimustine) polychemotherapy between March 1988 and February 1993. Complete remission was achieved in 4 patients, partial remission in 8 patients, while 9 patients were unresponsive to treatment. None of the complete responders relapsed during the follow-up period, and the median duration of remission was 24 months. The median survival for the unresponsive and partially responsive patients was less than half a year. Side-effects included gastrointestinal symptoms, myelosuppression and alopecia, but treatment-related deaths did not occur. The present data confirm the favourable impact of CEP polychemotherapy on pretreated, advanced Hodgkin's disease patients.

Original languageHungarian
Pages (from-to)1187-1190
Number of pages4
JournalOrvosi hetilap
Issue number22
Publication statusPublished - May 29 1994


ASJC Scopus subject areas

  • Medicine(all)

Cite this